yahoo_financeOriginal article
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
Phase 2positiveNemolizumabPositive
AI Analysis
Summary
Phase II data for nemolizumab presented at PeDRA 2026 show long-term symptom relief in children aged 2 to 11 years with moderate-to-severe atopic dermatitis.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Phase II data show long-term symptom relief in children aged 2 to 11 years with moderate-to-severe atopic dermatitis
Importance:6/10
Sentiment:
0.60
atopic dermatitispediatricdermatologyPeDRA 2026Phase 2nemolizumab
Related Companies
Read the original article
Published by yahoo_finance on October 15, 2026 5:00 AM